Abstract: The present invention provides an oral pharmaceutical formulation comprising coated spheroids of a kinase inhibitor such as neratinib, which formulation is designed to reduce or eliminate side effects associated with existing oral formulations of kinase inhibitors.
Type:
Grant
Filed:
August 29, 2013
Date of Patent:
December 15, 2015
Assignee:
WYETH LLC
Inventors:
Sripriya Venkata Ramana Rao, Syed Muzafar Shah, Christopher Richard Diorio, Maja Vencl-Joncic, Eugene Murphy
Abstract: In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. Each mutant toxin includes a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may further include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to antibodies or binding fragments thereof that binds to said immunogenic compositions. In further aspects, the invention relates to isolated nucleotide sequences that encode any of the foregoing, and methods of use of any of the foregoing compositions.
Type:
Grant
Filed:
July 10, 2015
Date of Patent:
November 17, 2015
Assignee:
Wyeth LLC
Inventors:
Annaliesa Sybil Anderson, Maninder K. Sidhu, Robert G. K. Donald, Kathrin Ute Jansen, Narender K. Kalyan, Justin Keith Moran, Mark E. Ruppen, Michael James Flint
Abstract: The present invention provides a compound of formula I: wherein X?, R1, and R2 are as defined herein, and compositions thereof.
Type:
Grant
Filed:
July 2, 2014
Date of Patent:
November 10, 2015
Assignee:
Wyeth, LLC
Inventors:
Nataliya Bazhina, George Joseph Donato, III, Steven R. Fabian, John Lokhnauth, Sreenivasulu Megati, Charles Melucci, Christian Ofslager, Niketa Patel, Galen Radebaugh, Syed M. Shah, Jan Szeliga, Huyi Zhang, Tianmin Zhu
Abstract: This invention describes processes for the convergent synthesis of calicheamicin derivatives, and similar analogs using bifunctional and trifunctional linker intermediates.
Abstract: The present invention relates to Neisseria ORF2086 proteins, crossreactive immunogenic proteins which can be isolated from nesserial strains or prepared recombinantly, including immunogenic portions thereof, biological equivalents thereof, antibodies that immunospecifically bind to the foregoing and nucleic acid sequences encoding each of the foregoing, as well as the use of same in immunogenic compositions that are effective against infection by Neisseria meningitidis serogroup B.
Type:
Grant
Filed:
March 5, 2015
Date of Patent:
October 27, 2015
Assignee:
Wyeth Holdings LLC
Inventors:
Gary W. Zlotnick, Leah Diane Fletcher, John Erwin Farley, Liesel A. Bernfield, Robert J. Zagursky, Benjamin J. Metcalf
Abstract: The present invention provides a new composition for treating pain-associated sleep disturbances, especially shortened sleep duration, comprising ibuprofen and diphenhydramine. The composition is further prepared as a bilayer tablet or caplet, or alternatively as a soft gelatin capsule composition, to prevent interaction between the active ingredients.
Type:
Grant
Filed:
October 1, 2014
Date of Patent:
October 13, 2015
Assignee:
Wyeth LLC
Inventors:
Graham D. Cook, Todd S. Koch, David H. Giamalva, Justin Bianco, James J. Fort, Geraldine Doyle, Steven Cooper
Abstract: A pharmaceutical composition is provided which contains a water soluble acid salt of a sympathomimetic amine, e.g., pseudoephedrine, and an additive, e.g., a volatile amine or other odorant, that is co-distillable, e.g., by steam distillation, with the sympathomimetic amine and/or its derivatives, e.g., its free base.
Type:
Application
Filed:
June 15, 2015
Publication date:
October 1, 2015
Applicant:
Wyeth LLC
Inventors:
David Hugh Giamalva, Gary Bruce Anderson
Abstract: This invention relates to methods of using weak partitioning chromatography for the purification of a product from a load fluid containing one or more impurities. Further, the invention relates to methods of weak partitioning chromatography defined by operating conditions which cause a medium to bind least 1 mg of product per mL of medium, or alternatively, defined by a partition coefficient of at least 0.1.
Type:
Grant
Filed:
November 28, 2011
Date of Patent:
September 29, 2015
Assignee:
Wyeth LLC
Inventors:
Paul R. Brown, Jonathan Lee Coffman, Ranganathan Godavarti, Timothy Iskra, Brian D. Kelley, Suresh Vunnum, Shujun Sun, Tianning Yu, James Edward Booth, Mary Beth Switzer
Abstract: The present invention relates to maleate salt forms of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide, methods of preparing crystalline maleate salt forms, the associated compounds, and pharmaceutical compositions containing the same. The maleate salts are useful in treating cancers, particularly those affected by kinases of the epidermal growth factor receptor family.
Type:
Grant
Filed:
February 12, 2013
Date of Patent:
September 22, 2015
Assignee:
Wyeth LLC
Inventors:
Quinhong Lu, Mannching Sherry Ku, Warren Chew, Gloria Cheal, Anthony F. Hadfield, Mahmoud Mirmehrabi
Abstract: The present invention relates to Neisseria ORF2086 proteins, crossreactive immunogenic proteins which can be isolated from nesserial strains or prepared recombinantly, including immunogenic portions thereof, biological equivalents thereof, antibodies that immunospecifically bind to the foregoing and nucleic acid sequences encoding each of the foregoing, as well as the use of same in immunogenic compositions that are effective against infection by Neisseria meningitidis serogroup B.
Type:
Grant
Filed:
April 25, 2012
Date of Patent:
September 15, 2015
Assignee:
Wyeth Holdings LLC
Inventors:
Gary W. Zlotnick, Leah Diane Fletcher, John Erwin Farley, Liesel A. Bernfield, Robert J. Zagursky, Benjamin J. Metcalf
Abstract: The present invention relates to immunogenic conjugates comprising S. aureus serotype 5 and 8 capsular polysaccharides conjugated to carrier proteins and methods for their preparation and use. Methods for making the immunogenic conjugates of the invention involve covalent conjugation of the capsular polysaccharides with the carrier proteins using conjugation chemistry involving either 1,1-carboyl-di-1,2,4-triazole (CDT) or 3-(2-pyridyldithio)-propionyl hydrazide (PDPH).
Type:
Grant
Filed:
June 22, 2010
Date of Patent:
September 8, 2015
Assignee:
Wyeth LLC
Inventors:
Stephen John Freese, Annaliesa Anderson, Viliam Pavliak, Kathrin Ute Jansen, Ingrid Lea Scully, Tracy Dee Scott, Jasdeep Singh Nanra, A. Krishna Prasad, Bruce Arthur Green
Abstract: The present invention is directed to methods of producing conjugates of A? peptide immunogens with protein/polypeptide carrier molecules, which are useful as immunogens, wherein peptide immunogens are conjugated to protein carriers via activated functional groups on amino acid residues of the carrier or of the optionally attached linker molecule, and wherein any unconjugated reactive functional groups on amino acid residues are inactivated via capping, thus retaining the immunological functionality of the carrier molecule, but reducing the propensity for undesirable reactions that could render the conjugate less safe or effective. Furthermore, the invention also relates to such immunogenic products and immunogenic compositions containing such immunogenic products made by such methods.
Type:
Grant
Filed:
February 14, 2012
Date of Patent:
September 8, 2015
Assignees:
Janssen Sciences Ireland UC, Wyeth LLC
Inventors:
Rasappa G. Arumugham, A. Krishna Prasad, Michael Hagen
Abstract: A number of ?-hemolytic streptococci polynucleotides and polypeptides, particularly Streptococcus pyogenes polypeptides and polynucleotides, are described. Two or more of the polypeptides of the invention can be formulated for use as immunogenic compositions. Also disclosed are methods for immunizing against and reducing infection caused by ?-hemolytic streptococci.
Type:
Grant
Filed:
July 16, 2013
Date of Patent:
September 8, 2015
Assignees:
Regents of the University of Minnesota, Wyeth LLC
Inventors:
Ingrid Lea Scully, Annaliesa Sybil Anderson, Michael Hagen, Stephen Bruce Olmsted, Paul Patrick Cleary
Abstract: The present invention provides for antibodies that bind to Notch1. The present disclosure also provides methods of making the antibodies, pharmaceutical compositions comprising these antibodies and methods of treating disorders with the antibodies and pharmaceutical compositions.
Type:
Grant
Filed:
December 9, 2011
Date of Patent:
September 8, 2015
Assignee:
Wyeth LLC
Inventors:
Kenneth G. Geles, Bin-Bing Stephen Zhou, Lioudmila Gennadievna Tchistiakova, Yijie Gao, Joel Bard
Abstract: The present invention provides a taste-masked sunscreen composition comprising at least one sunscreen and a spider ester wherein the sunscreen and the spider ester are in intimate association. A method of making the taste-masked sunscreen composition is provided.
Type:
Grant
Filed:
October 12, 2010
Date of Patent:
September 8, 2015
Assignee:
Wyeth LLC
Inventors:
Bhalchandra Somabhai Patel, Jay Roberts Dickerson, Gary Robert Agisim, Richard John Kenny
Abstract: The present invention relates to immunogenic compositions, comprising polypeptides and polysaccharides from Staphylococcus aureus. The present invention also relates to immunogenic compositions, comprising Staphylococcus aureus capsule polysaccharides conjugated to a carrier protein. In addition, the invention relates to methods of inducing an immune response in subjects against Staphylococcus aureus using immunogenic compositions of the Staphylococcus aureus polypeptides and capsule polysaccharides.
Type:
Grant
Filed:
October 15, 2014
Date of Patent:
August 25, 2015
Assignee:
Wyeth LLC
Inventors:
Annaliesa Anderson, Viliam Pavliak, Kathrin Ute Jansen, Ingrid Lea Scully, Steven Morris Baker, Jasdeep Singh Nanra, Ellen Murphy, Bruce Arthur Green, Mark Edward Ruppen, Yekaterina Timofeyeva
Abstract: Sodium ibuprofen compositions and methods of manufacturing tablets and caplets comprising sodium ibuprofen are described. The formulation is advantageous because it allows for the formation of tablets having low sodium content and further provides tablets exhibiting improved physical stability, high tablet hardness and high strength, coupled with excellent dissolution and bioavailability characteristics. The formulations and processes are further advantageous because they can be produced in large quantities without an unacceptable number of defective tablets.
Type:
Application
Filed:
April 24, 2015
Publication date:
August 20, 2015
Applicant:
Wyeth LLC
Inventors:
Jeffery Jon Seyer, Amy Lee Conder, Angela Pearce Taylor, Bonny Rene Shaw
Abstract: The present invention relates to Neisseria ORF2086 proteins, crossreactive immunogenic proteins which can be isolated from nesserial strains or prepared recombinantly, including immunogenic portions thereof, biological equivalents thereof, antibodies that immunospecifically bind to the foregoing and nucleic acid sequences encoding each of the foregoing, as well as the use of same in immunogenic compositions that are effective against infection by Neisseria meningitidis serogroup B.
Type:
Grant
Filed:
March 20, 2009
Date of Patent:
August 18, 2015
Assignee:
Wyeth Holdings LLC
Inventors:
Gary W. Zlotnick, Leah Diane Fletcher, John Erwin Farley, Liesel A. Bernfield, Robert J. Zagursky, Benjamin J. Metcalf
Abstract: The present invention provides a new forms of (R)—N-methylnaltrexone, and compositions thereof, useful as a peripheral mu opioid receptor antagonist.
Type:
Grant
Filed:
November 21, 2012
Date of Patent:
August 11, 2015
Assignees:
Wyeth LLC, Progenics Pharmamceuticals, Inc.
Inventors:
Valeriya N. Smolenskaya, Kadum A. Al Shareffi, Julio Perez, Syed M. Shah, Thomas A. Boyd
Abstract: The present invention is directed to methods of producing conjugates of A? peptide immunogens with protein/polypeptide carrier molecules, which are useful as immunogens, wherein peptide immunogens are conjugated to protein carriers via activated functional groups on amino acid residues of the carrier or of the optionally attached linker molecule, and wherein any unconjugated reactive functional groups on amino acid residues are inactivated via capping, thus retaining the immunological functionality of the carrier molecule, but reducing the propensity for undesirable reactions that could render the conjugate less safe or effective. Furthermore, the invention also relates to such immunogenic products and immunogenic compositions containing such immunogenic products made by such methods.
Type:
Grant
Filed:
August 20, 2007
Date of Patent:
August 4, 2015
Assignees:
Janssen Sciences Ireland UC, Wyeth LLC
Inventors:
Rasappa G. Arumugham, A. Krishna Prasad, Michael Hagen